Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Phaeophyceae, commonly known as brown seaweeds (such as kelp, Fucus, and Laminaria), have been investigated for their potential antithrombotic activity. The primary scientific interest centers on their content of sulfated polysaccharides, especially fucoidans. Fucoidans have demonstrated anticoagulant, antithrombotic, and fibrinolytic activities in various in vitro and animal studies. These mechanisms are thought to be similar to those of heparin, involving inhibition of thrombin and factor Xa, and enhancement of antithrombin III activity, which can reduce blood clot formation.

Several preclinical studies have shown that fucoidans extracted from different brown seaweed species can prolong clotting time and reduce thrombus formation in animal models. Some studies also suggest anti-platelet aggregation effects. However, clinical data in humans are very limited. There are a few small, early-phase clinical trials or case reports, and no large-scale, randomized controlled trials have confirmed efficacy or safety for treating or preventing thrombosis in humans. Therefore, while there is a scientific rationale and promising preclinical data, the overall evidence remains preliminary and insufficient for widespread clinical recommendation.

Historically, brown seaweeds have not been specifically used in traditional medicine for thrombosis, so traditional evidence is lacking. Current use is based on modern pharmacological research rather than long-standing historical practices.

More about Phaeophyceae (unspecified)
More about Thrombosis

Other ingredients used for Thrombosis

Other health conditions supported by Phaeophyceae (unspecified)

Products containing Phaeophyceae (unspecified)